Dysfunctional DC subsets in RCC patients: Ex vivo correction to yield an effective anti-cancer vaccine

M. Gigante a,1, A. Blasi c,1, A. Loverre d, V. Mancini d, M. Battaglia d, F.P. Selvaggi d, E. Maiorano e, A. Napoli e, G. Castellano d, W.J. Storkus f, L. Gesualdo a, c, E. Ranieri a, b, ∗

a Bioagromed, University of Foggia, via Napoli, 71100 Foggia, Italy
b Dept. of Biomedical Sciences, Division of Clinical Pathology, University of Foggia, Ospedali Riuniti, viale L. Pinto, 71100 Foggia, Italy
c Dept. of Biomedical Sciences, Division of Nephrology, University of Foggia, Ospedali Riuniti, viale L. Pinto, 71100 Foggia, Italy
d Dept. of Emergency and Organ Transplantation, University of Bari, Piazza G. Cesare 11, 70124 Bari, Italy
e Dept. of Pathological Anatomy, University of Bari, Piazza G. Cesare 11, 70124 Bari, Italy
f Dept. of Dermatology, University of Pittsburgh School of Medicine, 200 Lothrop Street, Pittsburgh, PA, 15213, United States

ARTICLE INFO

Article history:
Received 24 July 2008
Accepted 8 September 2008
Available online xxx

Keywords:
Renal cell carcinoma
Dendritic cells
lymph nodes
Confocal microscopy
T cell response

ABSTRACT

Dendritic cells (DCs) are potent antigen-presenting cells responsible for the activation and functional polarization of specific T cells. In patients with renal cell carcinoma (RCC) and other cancers, coordinate DC and T cell defects have been reported. In particular, DC and T cell functional subsets that are not conducive to tumor clearance are hypothesized to predominate in patients with advanced-stage disease. Two major peripheral blood DC subsets have been identified in humans: myeloid dendritic cells (mDCs) and plasmacytoid dendritic cells (pDCs) that are believed to mediate contrasting effects on cancer immunity. Given the lack of information regarding DC subsets in patients with RCC, in the present study we have investigated the comparative frequencies and activation states of mDC and pDC in peripheral blood, cancer tissues and lymph nodes of patients with RCC using flow cytometry and immunohistochemistry. Three monoclonal antibodies (mAbs) reactive against specific DC subsets (BDCA-2 or BDCA-4 for pDC and BDCA-1 and BDCA-3 which represent two distinct subsets of mDC, mDC1 and mDC2, respectively) were employed. We observed a significant reduction of both DC subsets in the peripheral blood of patients as compared to normal donors. Similarly, both mDC and pDC were recruited in large numbers into RCC tumor tissues, where they displayed an immature phenotype (DC-LAMP−) and appeared unable to differentiate into mature DC (CD83+). We readily able to generate ex vivo mDC from RCC patients. These DC stimulated robust anti-tumor CTL in vitro and would be envisioned for use in DC-based vaccines applied in patients with RCC whose existing immune system is judged dysfunctional, anergic or prone to undergo apoptosis.

© 2008 Elsevier Ltd. All rights reserved.

1. Introduction

Patients with advanced renal cell carcinoma (RCC) frequently exhibit immune dysfunction. Notably, patients with active, disseminated disease are typically characterized by predominant Th2- or T regulatory-type immunity (Tatsumi et al., 2002, 2003). While RCC lesions are commonly observed to contain tumor-infiltrating lymphocytes, these cells are typically reported to be “functionally inappropriate”, dysfunctional or pro-apoptotic, which is consistent with their inability to mediate clinically beneficial outcomes in vivo (Van den Hove et al., 1997; Kolbeck et al., 1992).

Dendritic cells (DC) are the most potent antigen-presenting cells (APC) and continue to receive enormous attention as a “natural adjuvant” to be integrated in therapeutic vaccines in the cancer setting (Steinman, 1991). Induction of an effective anti-tumor response requires the active participation of DC, responsible for the capture of tumor-specific antigens (Ag) and transport of this “information” to regional lymphoid tissues, where tumor-specific T cells may be cross-primed. DC are heterogeneous in nature, being comprised of multiple cell subsets that display differences in terms of phenotype, functionality and tissue localization. Two major subsets of human blood DC have been defined (O’Doherty et al., 1994), and techniques for their isolation have been established (Dzionek et al., 2000). CD11c+/CD123dim/BDCA1+ DC, classically defined as “myeloid” DC (mDC), phagocytose antigens within their microen-
viorment and tend to be potent stimulators of Th1-type polarized T cell responses. In contrast, CD11c-CD123+/BDCA-2+ "plasmacytoid" DC (pDC) are poorly phagocytic when compared to mDC, and tend to support Th2-type immunity (Reid et al., 2000).

The presence of cancer leads to numerical and functional abnormalities of DC subsets in various tissues (blood, tumor and draining lymph nodes) that facilitate tumor-induced immune escape. Indeed, several reports have demonstrated that DC infiltrating a wide range of tumors have a deficient ability to stimulate anti-tumor T cell responses in vitro and in vivo (Perrot et al., 2007; Stoitzner et al., 2008). RCC tumors may prevent the induction of the immune response by releasing immunosuppressive factors including TGF-β, IL-10, gangliosides, products of oxidative stress and thrombospondin that inhibit immune responses by coordinately dampening down both DC and T cell function (Curiel et al., 2004; Kudo et al., 2003; Lusini et al., 2001). This microenvironment limits the degree of DC maturation and trafficking to lymph nodes, a process that is normally associated with prolonged survival and a reduced incidence of metastases in patients with various human cancers including melanoma, gastric, breast, oral, and lung carcinoma (Ladányi et al., 2007; Tabarkiewicz et al., 2008; Iwamoto et al., 2003; Reichert et al., 2001). In the light of their profound importance to anti-tumor immunity, surprisingly little is known about the frequency or function of DC in RCC patients.

Using a panel of antibodies recognizing DC subsets and maturation markers (Dzionek et al., 2000), the primary goal of this study was to determine the comparative frequencies of the two major DC subsets in the peripheral blood and tumor tissues of 30 RCC patients as compared to 40 healthy individuals. Tumor-draining lymph nodes (LN) were also evaluated for mDC vs. pDC frequencies in 13 of these patients. We report that the frequency of both DC subsets was significantly lower in the peripheral blood of RCC patients than of healthy controls, and that both DC subsets could be imaged in large numbers within RCC tissue, where they persist in an immature state that appeared incompetent to migrate into secondary lymphoid tissue. We also noted that peripheral, dysfunctional APC isolated from patients (Jonuleit et al., 1997) could be rendered immunostimulatory after in vitro culture in the presence of IL-2 and IL-7. These ex vivo generated mDC promoted superior CTL activity when loaded with RCC lysate as a source of tumor antigens and may constitute a novel vaccine component for patients with RCC.

2. Materials and methods

2.1. Antibodies

The mouse mAb anti-CD1c (.374o0000rleityph9-402(do)9-40c-18i.4(IL-7)92.6(.)-333.4ce7((pe54.7(a)-254s10(e71.8(po720(TIENCE0720(0.5(com

Goat Serum (Sigma) at room temperature in a dark and humidified container; (2) overnight at 4 °C in primary antibody diluted in blocking buffer (the anti-BDCA-1 and anti-BDCA-3 antibodies diluted 1:20, the anti-BDCA-4 and anti-DC-LAMP antibodies diluted 1:100) and (3) for 2 h with the appropriate secondary antibodies (Alexa Fluor 488 goat anti-mouse IgG, diluted 1:400, Molecular Probes) at room temperature. The sections were washed in PBS after each step, counterstained with TO-PRO-3 * nitrogen freezing followed by thawing at 37 °C × 5 cycles). Supernatants were passed through a 0.45-μm filter. Protein content was determined using a Bradford protein assay (Bio-Rad) and aliquots were stored at −80 °C until use. On day 6, to generate mature mDC were harvested and analyzed by flow cytometry, then tested (1000 U/ml; PeproTech) were added to culture. On day 8 of culture, analyzed and the images were sequentially scanned at the 3 wave-lengths. The number of BDCA-1+*, BDCA-3+, BDCA-4*, DC-LAMP* and CD11c*/CD83* cells was measured in at least 15 high power fields (HPF; 630×) per section by two independent observers blinded to the origin of the slides. The final count was the mean of the two measures. In no case the inter-observer variability exceed 20%.

### 2.6. Isolation of PBMC and preparation of mDC

Peripheral blood was obtained by venipuncture from 6 RCC patients with signed consent and peripheral blood mononuclear cells (PBMC) were isolated at the interface of ficoll-hypaque density gradient (Sigma Chemical Co., St. Louis, MO) per the manufacturer’s instructions, washed twice in PBS, re-suspended in AIM-V medium (Invitrogen-Life Technologies; Carlsbad, CA) and incubated at 37 °C for 2 h to allow the adhesion of monocytes to plastic. Adherent monocytes were cultured with 1000 U/ml GM-CSF and 1000 U/ml IL-4 (Schering-Plough) in AIM-V medium. DC were pulsed on day 5 with an average of 100 μg/ml tumor lysate at 37 °C overnight. Tumor cells lysate was obtained by 5 freeze-thaw cycles (liquid nitrogen freezing followed by thawing at 37 °C × 5 cycles). Supernatants were passed through a 0.45-μm filter. Protein content was determined using a Bradford protein assay (Bio-Rad) and aliquots were stored at −80 °C until use. On day 6, to generate mature mDC were harvested and analyzed by flow cytometry, then tested for their ability to stimulate RCC specific T cell responses in vitro.

### 2.7. Immunophenotypic analyses

Cells were washed and resuspended in FACS buffer (PBS pH 7.2, 0.2% BSA, and 0.02% sodium azide) containing 3% human serum analyzed and the images were sequentially scanned at the 3 wave-lengths. The number of BDCA-1+, BDCA-3+, BDCA-4+, DC-LAMP+ and CD11c+/CD83+ cells was measured in at least 15 high power fields (HPF; 630×) per section by two independent observers blinded to the origin of the slides. The final count was the mean of the two measures. In no case the inter-observer variability exceed 20%.

### Table 1

RCC patients evaluated in the study, considering age at time of surgery, sex, pathological stage, grade (Fuhrman), adjuvant treatment and at the last evaluation, follow-up months.

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age/sex</th>
<th>Stage</th>
<th>Grade</th>
<th>Adjuvant treatment</th>
<th>Last evaluation</th>
<th>Follow-up (months)</th>
</tr>
</thead>
<tbody>
<tr>
<td>DG</td>
<td>63/M</td>
<td>T1aN0M0</td>
<td>3</td>
<td>–</td>
<td>NED</td>
<td>55</td>
</tr>
<tr>
<td>CG</td>
<td>55/M</td>
<td>T1N0M0</td>
<td>1</td>
<td>–</td>
<td>NED</td>
<td>67</td>
</tr>
<tr>
<td>CA</td>
<td>74/M</td>
<td>T1aN0M0</td>
<td>2</td>
<td>–</td>
<td>NED</td>
<td>65</td>
</tr>
<tr>
<td>SO</td>
<td>46/F</td>
<td>T3aN0M0</td>
<td>2</td>
<td>–</td>
<td>NED</td>
<td>52</td>
</tr>
<tr>
<td>BM</td>
<td>76/F</td>
<td>T1N0M0</td>
<td>3</td>
<td>–</td>
<td>NED</td>
<td>39</td>
</tr>
<tr>
<td>CG</td>
<td>53/F</td>
<td>T3aN0M0</td>
<td>3</td>
<td>–</td>
<td>NED</td>
<td>53</td>
</tr>
<tr>
<td>LA</td>
<td>67/F</td>
<td>T3nM0</td>
<td>2</td>
<td>–</td>
<td>NED</td>
<td>58</td>
</tr>
<tr>
<td>MR</td>
<td>45/M</td>
<td>T3aN0M0</td>
<td>3</td>
<td>–</td>
<td>NED</td>
<td>71</td>
</tr>
<tr>
<td>ZG</td>
<td>58/M</td>
<td>T3aN0M0</td>
<td>3</td>
<td>–</td>
<td>NED</td>
<td>103</td>
</tr>
<tr>
<td>RG</td>
<td>66/M</td>
<td>T3nM0</td>
<td>3</td>
<td>–</td>
<td>NED</td>
<td>32</td>
</tr>
<tr>
<td>SL</td>
<td>49/F</td>
<td>T3nM0</td>
<td>1</td>
<td>–</td>
<td>NED</td>
<td>60</td>
</tr>
<tr>
<td>PT</td>
<td>52/F</td>
<td>T3nM0</td>
<td>2</td>
<td>–</td>
<td>NED</td>
<td>57</td>
</tr>
<tr>
<td>CB</td>
<td>82/M</td>
<td>T1N0M0</td>
<td>1</td>
<td>–</td>
<td>NED</td>
<td>46</td>
</tr>
<tr>
<td>RS</td>
<td>45/M</td>
<td>T2N0M0</td>
<td>2</td>
<td>C, RT, S</td>
<td>Mets, bone</td>
<td>22</td>
</tr>
<tr>
<td>RA</td>
<td>29/M</td>
<td>T1N0M0</td>
<td>2</td>
<td>–</td>
<td>NED</td>
<td>67</td>
</tr>
<tr>
<td>PG</td>
<td>67/F</td>
<td>T3nM0</td>
<td>2</td>
<td>–</td>
<td>NED</td>
<td>63</td>
</tr>
<tr>
<td>CL</td>
<td>77/M</td>
<td>T1N0M0</td>
<td>2</td>
<td>–</td>
<td>NED</td>
<td>28</td>
</tr>
<tr>
<td>CM</td>
<td>78/F</td>
<td>T3nM0</td>
<td>3</td>
<td>–</td>
<td>Mets, lung-spleen</td>
<td>62</td>
</tr>
<tr>
<td>NC</td>
<td>81/M</td>
<td>T1N0M0</td>
<td>1</td>
<td>S, IL-2</td>
<td>Mets, lung</td>
<td>57</td>
</tr>
<tr>
<td>SL</td>
<td>53/M</td>
<td>T3nM0</td>
<td>3</td>
<td>C, IL-2</td>
<td>Mets, lung</td>
<td>41</td>
</tr>
<tr>
<td>GR</td>
<td>69/M</td>
<td>T3nM0</td>
<td>3</td>
<td>–</td>
<td>Mets, lungs</td>
<td>41</td>
</tr>
<tr>
<td>CA</td>
<td>72/M</td>
<td>T1N0M0</td>
<td>1</td>
<td>–</td>
<td>NED</td>
<td>40</td>
</tr>
<tr>
<td>TC</td>
<td>62/M</td>
<td>T3nM0</td>
<td>1</td>
<td>RT, S</td>
<td>Mets, bone</td>
<td>54</td>
</tr>
<tr>
<td>BM</td>
<td>53/M</td>
<td>T1N0M0</td>
<td>2</td>
<td>–</td>
<td>NED</td>
<td>36</td>
</tr>
<tr>
<td>SV</td>
<td>68/M</td>
<td>T3nM0</td>
<td>1</td>
<td>–</td>
<td>NED</td>
<td>32</td>
</tr>
<tr>
<td>DeG</td>
<td>60/M</td>
<td>T3nM1</td>
<td>2</td>
<td>–</td>
<td>Mets, lungs</td>
<td>18</td>
</tr>
<tr>
<td>PS</td>
<td>76/F</td>
<td>T3nM0</td>
<td>2</td>
<td>–</td>
<td>NED</td>
<td>18</td>
</tr>
<tr>
<td>TN</td>
<td>74/F</td>
<td>T3nM0</td>
<td>2</td>
<td>–</td>
<td>NED</td>
<td>25</td>
</tr>
</tbody>
</table>

Abbreviations used: C, chemotherapy; M, metastatic disease; S, surgery; IL-2, interleukin 2 therapy; RT, radiotherapy; NED, no evidence of disease.

Confocal microscopy was performed using a Leica TCS SP2 microscope equipped with argon-krypton (488 nm), green-neon (543 nm) and helium-neon (633 nm) lasers. Confocal images were taken at 500-nm intervals on z-axis of the section covering a total 6 μm depth. Images from individual optical planes and multiple serial optical sections were analyzed and the images were sequentially scanned at the 3 wave-lengths. The number of BDCA-1+, BDCA-3+, BDCA-4+, DC-LAMP+ and CD11c+/CD83+ cells was measured in at least 15 high power fields (HPF; 630×) per section by two independent observers blinded to the origin of the slides. The final count was the mean of the two measures. In no case the inter-observer variability exceed 20%.

### 2.5. Confocal laser scanning microscopy

Confocal microscopy was performed using a Leica TCS SP2 microscope equipped with argon-krypton (488 nm), green-neon (543 nm) and helium-neon (633 nm) lasers. Confocal images were taken at 500-nm intervals on z-axis of the section covering a total 6 μm depth. Images from individual optical planes and multiple serial optical sections were analyzed and the images were sequentially scanned at the 3 wave-lengths. The number of BDCA-1+, BDCA-3+, BDCA-4+, DC-LAMP+ and CD11c+/CD83+ cells was measured in at least 15 high power fields (HPF; 630×) per section by two independent observers blinded to the origin of the slides. The final count was the mean of the two measures. In no case the inter-observer variability exceed 20%.
Fig. 1. Circulating mDC and pDC in RCC patients. (A) Blood samples were obtained from 30 RCC patients and 40 healthy volunteers. Four-color flow cytometry was used to distinguish mDC and pDC subsets within freshly isolated peripheral blood mononuclear cells using specific antibodies directed against mDC1 (anti-BDCA1), mDC2 (anti-BDCA3), and pDC (anti-BDCA2). *P < 0.01 for all tested subpopulations. (B) The frequency of DC subsets in metastatic RCC patients (METS) vs. patients with no evidence of disease (NED) at last clinic evaluation of disease. *P < 0.05; **P < 0.01.

2.8. In vitro stimulation (IVS) of T cells

Previously harvested peripheral blood lymphocytes (PBL), were cultured at 1–2 × 10^6 per well in 24 well plates containing RPMI/10% heat-inactivated pooled human serum [Sigma (medium M2)] along with autologous DC pulsed with renal tumor lysate (at a 10:1 T cell:DC ratio), in the presence of 1 ng/ml IL-12p70 (R&D Systems, Minneapolis, MN) and 1000 UI/ml IL-6 (PeproTech). Responder lymphocytes were re-stimulated twice on a weekly schedule with mature DC in RPMI/10% human serum AB supplemented with IL-2 (20 units/ml; Proleukin; Novartis) and IL-7 (5 ng/ml; R&D Systems, Minneapolis, MN).

2.9. ELISPOT assays

On day 21 of the IVS cultures, T cells were assessed for their effector cytokine profiles using h-IFN-γ ELISPOT assays (BD-PharMingen; San Diego, CA), as recently described (Tatsunami et al., 2002). T cells were added to ELISPOT wells along with tumor lysate-loaded DC at a 10:1 T cell:DC ratio and plates were subsequently incubated at 37 °C for 24 h to detect IFN-γ producing cells. Determinations were performed in triplicate and spots were enumerated using an automatic plate reader (Zeiss-Kontron, Jena, Germany).

2.10. Statistical considerations

All data are expressed as means ± S.D. Statistical differences between groups were evaluated using 2-tailed Student’s t-test, and P values <0.05 were considered significant.

3. Results

3.1. Assessment of the frequency of DC subsets in the peripheral blood of RCC patients

We investigated the comparative frequencies of mDCs and pDCs in a group of 30 RCC patients and 40 healthy donors (MacDonald et al., 2002). Table 1 summarizes two patient cohorts assessed: patients with documented metastases at their last clinic evaluation (n = 7) and patients with no evidence of disease (n = 23).

We identified two subpopulations of circulating blood mDCs (i.e. mDC1 are BDCA-1+; mDC2 are BDCA-3+) and pDCs as BDCA-2+ cells. As shown in Fig. 1A, among the RCC patients the frequency and the absolute number of both DC subpopulations (DC total) were significantly reduced when compared with normal donor controls (P<0.01). The obtained frequencies of mDC1, mDC2 and pDC were 0.23 ± 0.18%, 0.22 ± 0.11% and 0.01 ± 0.01%, respectively, while the absolute numbers of cells were 15949 ± 4558, 14836 ± 7304 and 864 ± 564, respectively. In the control group, the percentages of mDC1, mDC2 and pDC were 0.30 ± 0.12%, 0.29 ± 0.12% and 0.03 ± 0.01%, respectively and the absolute numbers of cells were 20393 ± 7730, 19888 ± 8419 and 1897 ± 866, respectively. As shown in Fig. 1B, the median frequency of mDC1 was significantly increased in metastatic RCC patients (0.31%) when compared...
with patients with no evidence of disease or normal donor controls (P<0.05). A reduced frequency of mDC1 was observed in RCC patients with no evidence of disease vs. normal donor controls (P<0.05). Interestingly, we did not find a reduction of the circulating levels of total leukocytes in patients, suggesting that the decrease in DC frequencies was not correlated with a variation in peripheral blood mononuclear cells number (data not shown).

3.2. In situ characterization of DC in RCC tumors and tumor-draining lymph nodes

The low proportion of DC in the peripheral blood of RCC patients could be explained by at least two potential mechanisms: (i) preferential attraction of DC into patient tissues, or (ii) defective development of DC from bone marrow precursors. To evaluate these possibilities, we analyzed renal biopsies isolated from RCC and healthy controls (Fig. 3).

normal patients for the presence of mDC (Dzionek et al., 2000). Indirect immunofluorescence and confocal microscopy analyses revealed a high number of infiltrating immature myeloid DC to be present within the interstitial areas of renal biopsies obtained from RCC patients when compared to normal kidney. Interestingly, the number of infiltrating BDCA1+ mDC1 was most clearly increased in RCC patients, suggesting its likely efficient recruitment from the peripheral blood (Fig. 2A and B). The pattern for BDCA-3 staining resembled that for BDCA-1 (Fig. 2E and F). Interestingly, BDCA3+ mDC2 exhibited longer dendritic processes surrounding kidney tubular epithelial cells when compared to BDCA1+ DC1 (Fig. 2E, zoom). Overall, the mDC1/mDC2 frequencies in RCC tissues were significantly increased (BDCA-1+ cells: \( P = 0.01 \); BDCA-3+ cells: \( P = 0.04 \)) when compared to normal kidney tissue (Fig. 4).

3.3. Analysis of BDCA-4 expression in RCC vs. normal kidney tissue

We next investigated RCC vs. normal kidney tissues for expression of BDCA-4, an antigen that is highly restricted to pDC in both the blood and peripheral tissues (Tatsumi et al., 2002, 2003). Immunofluorescence analyses of frozen tissues showed that under normal conditions, pDCs are very rare in peripheral tissues, as they can migrate directly from blood to lymphoid tissues via high endothelial venules (Cella et al., 1999). On the contrary, we observed massive infiltration of RCC tissues by BDCA4+ pDC in all tubulointerstitial areas (Fig. 2C and D). When compared with normal kidney tissues, this difference in pDC infiltration was highly significant (\( P = 0.01 \); Fig. 4).

3.4. Analysis of the state of DC maturation in RCC vs. normal kidney tissue

To investigate the relative state of activation for kidney infiltrating DCs, we analyzed these cells for their expression of DC-LAMP, a protein belonging to the family of lysosomal-associated glycoproteins and considered to represent a highly specific marker of human DC maturation (Saint-Vis et al., 1998). Indirect immunofluorescence and confocal microscopy analyses suggest that DC-LAMP+...
cells were rare events in RCC tissue, with the few positive cells being randomly distributed within the interstitial area of the kidney (Fig. 3A and B, respectively). This data is consistent with that obtained for other peripheral tissues, with infiltrating DC bearing an immature phenotype. We noted no significant difference in the frequency of DC-LAMP+ frequencies in RCC vs. normal kidney tissue (P = 0.2; Fig. 4).

3.5. Analysis of DC in the tumor-draining lymph nodes of RCC patients

In response to pathogens or inflammatory stimuli, peripheral DC undergo phenotypic and functional maturation, leading to their migration via the afferent lymphatic system to the T-cell-rich areas of lymph nodes. After their arrival, they encounter naive T-cells and initiate adaptive immune responses (von Andrian and Mempel, 2003). There is accumulating evidence that the LN represents a primary basin of tumor-induced DC/T cell dysfunction (Poindexter et al., 2004; Lee et al., 2005).

To elucidate DC frequencies within LN and determine whether they displayed altered phenotypes, lymph node sections were analyzed by immunofluorescence (confocal) microscopy using mAbs directed against CD11c (myeloid DC) and CD83 (mature DC; Lechmann et al., 2001). LN harvested from a total of 12 RCC patients and 4 normal subjects were inspected. RCC-LN were generally characterized by high-frequencies of CD11c+ DCs, most of which were of a CD11c+CD83− phenotype (Fig. 5A and B). Frequencies of CD11c/CD83 dual-positive cells were statistically different when comparing RCC-LN vs. lymph nodes harvested from normal donors (P = 0.01). These data are in accordance with previous reports in other human cancers (melanoma, breast and lung cancer), in which, the degree of infiltration by mature DCs was inversely correlated with prolonged survival and a reduced incidence of metastases (Movassagh et al., 2004).

3.6. Functional assessment of ex vivo generated mDC1 to promote specific Type-1 T cell responses in RCC patients in vitro

Given the comparative reduction in circulating levels of mDC1 in RCC patients, that are believed to be required for optimal Type-1 anti-tumor immunity, we next chose to evaluate whether mDC1 could be generated ex vivo from peripheral blood precursors isolated from these patients. In particular, we wanted to assess whether such cultured mDC1 would be competent to promote the effective development of tumor-specific CTL. mDC1 were generated from 6 RCC patients, pulsed with autologous RCC lysate and then used as an in vitro stimulus for autologous peripheral blood T cells. mDC1 were generated according to standard procedure using rGM-CSF and rIL-4 supplementation for 6 days, followed by application of cytokine maturation-cocktail (i.e. IL-1β + TNF-α + IL-6 + PGE2) for 2 additional days. These cells exhibited a fully mature surface phenotype (de Vries et al., 2003) based on high expression levels of the CD80, CD83, CD86 and CCR7 markers (data not shown).

T cell lines obtained after multiple rounds of stimulation using antigen-loaded mDC1 were harvested at day 21 of culture and

Fig. 7. Phenotypes of memory/effector responder T cells. Expression of the CD45RO, CD62L, CCR7, CD27 and CD28 cell surface molecules was analyzed on CD8+ T cells after DC-based in vitro stimulation. Data shown are gated on CD8+ T cells and quadrants were established based on T cell staining with isotype control mAbs. Results are depicted for one patient RCC, but are representative of the 6 RCC patients evaluated.
tested for Type-1 functional status using IFN-γ ELISPOT readout assays. We analyzed the specificity of CTL responses under basal conditions (T0) and after 21 days of in vitro stimulation (T21). As shown in Fig. 6, at T0, T cells displayed a low degree of reactivity against mDC pulsed with autologous tumor lysate. After in vitro stimulation (T21), there was a strong increase in IFN-γ-secreting T cells responding against the same stimulus (P < 0.001). T21 T cells also exhibited significant, albeit lower level, responses against autologous tumor cells themselves.

We further characterized the tumor-specific T cells generated using mDC1-based stimulations, focusing on markers of T cell activation, proliferation and differentiation (Fig. 7). Staining of isolated T cells after in vitro stimulation with lysate-loaded mDC1 showed that a majority of CD8+ T cells expressed a CD45RA-CD62L-CD28+ phenotype, consistent with “central memory” T cells (Sallusto et al., 2004). Such T cells would be presumed to more readily respond to antigenic stimulation given their capacity to home to the lymph node, where they may be induced to expand and generate both memory and effector anti-tumor T cells. Importantly, these cells were also determined to express both CD27 and CD28, a phenotype that has been linked to long-term persistence after adoptive transfer into cancer patients (Powell et al., 2005; Ochsenbein et al., 2004). When taken collectively, these results suggest that: (i) mDC1 can be reproducibly generated from the blood of RCC patients and (ii) mDC1 can effectively promote the in vitro activation and expansion of Type-I anti-tumor T cells (that might be applied in adoptive immunotherapy approaches for these patients).

4. Discussion and conclusion

In the present study, using a panel of antibodies recognizing DC subsets and their maturation markers, we investigated the presence of both mDC and pDC subpopulations in the peripheral blood, tumor tissue and lymph nodes of RCC patients. We found a significantly lower percentage of both types of DC in the peripheral blood of RCC patients when compared with healthy donors. Clearly, such reductions in systemic DC frequencies could be related to the inhibitory effects of tumor-elaborated factors, such as IL-6, IL-10, VEGF and/or gangliosides (among others) that block DC maturation or promote their apoptosis (Kudo et al., 2003; Lusini et al., 2001). Alternatively, lower levels of DC subsets in the blood could reflect the recruitment of DC into the tissues of RCC patients. Indeed, we noted a significantly higher number of infiltrating mDC (BDCA-1+ and BDCA-3+) and pDC (BDCA-4+) in RCC tissues when compared to normal donor kidney tissues. However, these cells did not express the maturation marker DC-LAMP that is considered prognostic of the ability of these APC to stimulate immune response associated with the extended survival of melanoma patients (Movassagh et al., 2004). Indeed, immature or incompletely matured mDC, as well as, pDC may promote immune tolerance rather than immune activation against tumor-associated antigens (Steinman, 1991). They may also promote T-cell anergy or activate regulatory T cells (Curiel et al., 2004).

To determine whether tumor-associated alterations in the mDC and pDC numbers/phenotype extended to additional tissues, we analyzed the tumor-draining lymph node (LN) of 6 RCC patients, that is the first node accessed by cells leaving the tumor site via the lymphatic ducts and is a principal site in which anti-tumor T-cell priming may occur in cancer patients. Previous studies have demonstrated that the extent of mature DC trafficking to LN is correlated with local expansion of efficient anti-tumor T-cell-mediated immune responses and a favourable clinical outcome in melanoma patients (Ladányi et al., 2007). Interestingly, we observed a significantly lower degree of mature myeloid-derived DC (CD11c+CD83+) infiltration when compared to normal controls and it was in conflict with the physiological status where mature DC present tumor antigens to naïve T cells, resulting in T cell activation and differentiation. On the contrary, we found a high frequency of immature DC. The interference with maturation of myeloid-derived DC subset, which appears to be linked to the presence of tumor, could well contribute to immunosuppression of RCC patients and their failure to establish an effective anti-tumor immune response. Collectively, these data suggest that DC in RCC patients may be sequestered within tumor lesions where that exhibit reduced antigen-presenting function. Inefficient antigen presentation extends to the tumor-draining lymph node, thereby limiting the generation of protective anti-tumor immune responses in these individuals.

Despite the apparent disease-associated alterations in RCC patient DC subpopulations, we chose to next evaluate whether immunogenic DC could be developed from these individuals using an ex vivo culture approach. DC loaded with tumor antigens are considered an effective vaccine modality and has proven both safe and immunogenic in phase I/II clinical trials for a range of cancer types. Hence, the use of fully functional DC (i.e. DC1-type cells) in RCC immunotherapy would appear to represent a promising modality to elicit/expand or “reform” clinically beneficial Type-1 anti-tumor immune responses. Such approaches are clearly warranted since RCC that has proven refractory to conventional treatment modalities, such as chemo- and radio-therapy. We observed that cultured patient DC exhibited a fully-mature surface phenotype expressing high levels of the maturation-associated markers CD54, CD80, CD40, CD86, CD83 and CCR7 (Scandella et al., 2002) and that these APC were capable of effectively promoting the in vitro expansion of RCC-specific, IFN-γ-producing T cells. Interestingly, we observed that in vitro stimulation of T cells with lysate-loaded MoDCs induced higher percentages of CD45RO+, CCR7+, CD62L+ T cells, consistent with the “central memory” T cell phenotype associated with superior therapeutic potential in adoptive therapy applications (Klebanoff et al., 2005; Gattinoni et al., 2005). In this regard, the likely importance of DC1-based immunotherapy in RCC patients has been recently established in our previous study, where we demonstrated that mDC generated using IFN-α co-ordinately promote Type-1 anti-tumor immunity and decrease the potency of Treg responses in vitro (Gigante et al., 2008). These findings may have major implications for the development of therapeutic DC-based vaccines that focus on the resolution of uncontrolled DC activation.

Acknowledgements

This work was supported in part by grants: “Progetto Giovani Ricercatori” (2005) from University of Foggia, awarded to Margherita Gigante, and “Progetto Strategico della Regione Puglia (PS_012)”, 2006 to 2008, awarded to Elena Ranieri.

We are also grateful to Dr. Elisabetta Cavalcanti for critical reading of the manuscript.

References


